Core Viewpoint - Goldman Sachs analyst Bonnie Herzog maintains a Buy rating on Colgate-Palmolive Co (CL) with a price target of $106, despite mixed fourth-quarter results [1] Financial Performance - CL reported fourth-quarter earnings per share (EPS) of $0.91, exceeding expectations of $0.88/$0.89 [1] - Organic sales growth for the fourth quarter was 4.3%, which was below predictions, affected by a 50 basis point decline from lower private label volumes in Pet Nutrition [1][2] - The lower tax rate of 21.6% contributed a $0.04 boost to EPS, aiding in the small EPS beat for the quarter [3] Segment Performance - Hill's Pet Nutrition faced challenges in Europe, resulting in a miss in segment growth [2] - North America's organic sales declined by 0.7%, while Europe and APAC saw low-to-mid single-digit growth; Latin America and Africa/Eurasia experienced high single-digit increases [2] Future Guidance - Management provided initial FY25 guidance, which aligns with expectations, but foreign exchange headwinds are anticipated to impact net sales and possibly EPS [3] - The company's organic sales growth forecast of 3%-5% is consistent with its long-term target, factoring in the planned exit from private label pet nutrition in 2025 [4] Market Position - CL is considered a top-tier company in the HPC coverage, consistently outperforming and raising its FY24 outlook despite challenging market conditions [5] - The analyst expects a more balanced environment in FY25 with slower price growth and improved volume/mix trends [5] Risks and Challenges - Foreign exchange remains a potential risk, likely affecting gross margins and dollar EPS growth [6] - Despite weaker-than-expected organic sales growth, the company is expected to maintain healthy revenue growth driven by favorable market trends and market share expansion [6]

Core Insights - Colgate-Palmolive Company reported a decline in net sales for Q4 2024, missing the Zacks Consensus Estimate, while earnings per share (EPS) improved and exceeded expectations [1][2][3] Financial Performance - Net sales were $4,944 million, down 0.1% from $4,950 million in the previous year, and missed the consensus estimate of $4,987 million [3] - On an organic basis, sales grew by 4.3%, driven by a 2.5% increase in volume and a 1.8% improvement in pricing [4] - Gross profit increased to $2,982 million from $2,950 million year-over-year, with a gross profit margin expansion of 70 basis points to 60.3% [6] - Operating profit was $1,064 million, a slight decrease from $1,072 million in the prior year, with an operating profit margin contraction of 20 basis points to 21.5% [7] Market Position - Colgate maintained a leading position in the toothpaste market with a 41.4% global market share and a 32.2% share in the manual toothbrush market [5] Regional Performance - North America saw a 1% decline in net sales, while Latin America experienced a 7.2% decline due to unfavorable currency impacts, despite organic sales growth of 9.2% [8] - Europe’s net sales increased by 4.9%, driven by volume and pricing gains [9] - The Asia Pacific segment improved by 3.7% year-over-year, with a notable 5.8% increase in volume [10] - Africa/Eurasia's net sales rose by 2.8%, supported by an 11.5% increase in volume [10] - Hill's Pet Nutrition's net sales improved by 2.3% on a reported basis [11] Cash Flow and Shareholder Returns - The company ended Q4 2024 with cash and cash equivalents of $1,096 million and total debt of $7,949 million [12] - Net cash provided by operating activities was $4,107 million for the year, with $3.4 billion returned to shareholders through dividends and share repurchases [12] 2025 Outlook - Colgate expects flat net sales in 2025, with organic sales growth projected between 3% to 5% [14] - The company anticipates gross profit margin expansion and mid-single-digit growth in Base Business EPS for 2025 [15][16]

Group 1 - Colgate-Palmolive (CL) shares fell 5% after missing revenue forecasts and providing weak guidance due to foreign exchange impacts [1][5] - The company reported a revenue decline of 0.1% to $4.94 billion, missing the anticipated $4.98 billion [1][5] - Adjusted earnings per share (EPS) of $0.91 exceeded forecasts [1] Group 2 - Foreign exchange rates negatively impacted revenue by 4.4%, with Latin America experiencing a sales slump of 7.2% [2] - Sales in North America decreased by 1.0%, while Europe, Asia-Pacific, and Africa/Eurasia saw increases of 4.9%, 3.7%, and 2.8% respectively [2] - Sales at Hill's, which represents the largest percentage of total revenue, rose by 2.3% [2] Group 3 - CEO Noel Wallace stated that the company met its goals for the year, focusing on peer-leading growth and future investment [3] - For 2025, Colgate expects revenue to be "roughly flat" from 2024's $20.1 billion, anticipating a mid-single-digit negative impact from foreign exchange [3] - Visible Alpha estimates for 2025 revenue were $20.3 billion [3] Group 4 - Despite the recent drop, Colgate-Palmolive shares remain slightly higher over the past year [4]

Group 1 - The article emphasizes a dividend-focused value investment strategy that prioritizes capital preservation and steady income growth [1] - The author discusses a diversified dividend stock portfolio that includes high-quality value stocks with meaningful growth potential and long-term safety [1] Group 2 - There are no current stock or derivative positions in any mentioned companies, and no plans to initiate such positions in the near term [2] - The author may consider initiating a long position in Colgate-Palmolive Company through the sale of put options within the next 72 hours [3]

Core Insights - Colgate-Palmolive reported revenue of $4.94 billion for Q4 2024, a slight year-over-year decline of 0.1%, with an EPS of $0.91 compared to $0.87 a year ago, indicating a positive EPS surprise of +2.25% against the consensus estimate [1][2] Revenue Performance - North America net sales for Oral, Personal and Home Care reached $1.04 billion, exceeding the average estimate of $1.01 billion, reflecting a year-over-year increase of +3.7% [4] - Latin America net sales for Oral, Personal and Home Care were $1.11 billion, matching the average estimate but showing a decline of -7.2% year-over-year [4] - Africa/Eurasia net sales for Oral, Personal and Home Care were $269 million, surpassing the average estimate of $261.71 million, with a year-over-year increase of +2.7% [4] - Europe net sales for Oral, Personal and Home Care totaled $668 million, below the average estimate of $687.89 million, representing a year-over-year decline of -2.5% [4] - Asia Pacific net sales for Oral, Personal and Home Care were $724 million, closely aligning with the average estimate, showing a year-over-year increase of +3.7% [4] - Pet Nutrition net sales amounted to $1.14 billion, slightly below the average estimate of $1.17 billion, with a year-over-year increase of +2.3% [4] - Total Oral, Personal and Home Care net sales were $3.80 billion, matching the average estimate but reflecting a year-over-year decline of -0.8% [4] Profitability Metrics - Total operating profit for Oral, Personal and Home Care was $969 million, below the average estimate of $1.03 billion [4] - Corporate operating profit was reported at -$179 million, slightly better than the average estimate of -$184.13 million [4] - Pet Nutrition operating profit reached $275 million, exceeding the average estimate of $256.82 million [4] Stock Performance - Colgate-Palmolive shares returned +0.4% over the past month, underperforming the Zacks S&P 500 composite's +2.9% change, with a current Zacks Rank of 3 (Hold) indicating potential performance in line with the broader market [3]

Core Viewpoint - Colgate-Palmolive reported quarterly earnings of $0.91 per share, exceeding the Zacks Consensus Estimate of $0.89 per share, and showing an increase from $0.87 per share a year ago, indicating a positive earnings surprise of 2.25% [1][2] Financial Performance - The company achieved revenues of $4.94 billion for the quarter ended December 2024, which was below the Zacks Consensus Estimate by 0.86% and slightly lower than the $4.95 billion reported a year ago [2] - Over the last four quarters, Colgate-Palmolive has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance and Outlook - Colgate-Palmolive shares have remained flat since the beginning of the year, contrasting with the S&P 500's gain of 3.2% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $0.90, with expected revenues of $5.04 billion, and for the current fiscal year, the estimate is $3.76 on revenues of $20.37 billion [7] - The estimate revisions trend for Colgate-Palmolive is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Consumer Products - Staples industry, to which Colgate-Palmolive belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, indicating potential challenges ahead [8]

COLGATE-PALMOLIVE COMPANY 4Q & FULL YEAR 2024 EARNINGS PRESENTATION TIGHTLY FOCUSED ON FOUR ATTRACTIVE CORE CATEGORIES ORAL CARE PET NUTRITION JANUARY 31, 2025 January 2025 Notice for Investor Presentation Please review the following fourth quarter and full year 2024 earnings presentation in conjunction with our fourth quarter and full year 2024 earnings press release, our fourth quarter and full year 2024 prepared management remarks and additional information regarding our non-GAAP financial measures, incl ...

[Overall Financial Performance](index=1&type=section&id=Colgate%20Announces%204th%20Quarter%20and%20Full%20Year%202024%20Results) [Full Year 2024 Performance](index=1&type=section&id=Full%20Year) Full year 2024 saw record net sales of **$20.1 billion**, **7.4% organic growth**, and strong profitability and cash generation Full Year Total Company Results (Millions USD) | Full Year Total Company Results | 2024 | 2023 | Change | | :--- | :--- | :--- | :--- | | **GAAP** | | | | | Net Sales (Millions USD) | $20,101 | $19,457 | +3.3% | | Diluted EPS (USD) | $3.51 | $2.77 | +27% | | **Base Business (Non-GAAP)** | | | | | Organic Sales Growth | | | +7.4% | | Base Business Diluted EPS (USD) | $3.60 | $3.23 | +11% | - Achieved a milestone by delivering over **$20 billion** in Net sales for the first time[5](index=5&type=chunk) - Net cash provided by operations for the full year was **$4.11 billion**, a **10% increase** compared to 2023[5](index=5&type=chunk) - The company returned **$3.4 billion** in cash to shareholders through dividends and share repurchases[5](index=5&type=chunk) [Fourth Quarter 2024 Performance](index=1&type=section&id=Fourth%20Quarter) Q4 2024 saw nearly flat net sales at **$4.94 billion**, offset by **4.3% organic growth**, improved EPS, and **70 basis point** gross margin expansion Fourth Quarter Total Company Results (Millions USD) | Fourth Quarter Total Company Results | 2024 | 2023 | Change | | :--- | :--- | :--- | :--- | | **GAAP** | | | | | Net Sales (Millions USD) | $4,944 | $4,950 | -0.1% | | Diluted EPS (USD) | $0.90 | $0.87 | +3% | | **Base Business (Non-GAAP)** | | | | | Organic Sales Growth | | | +4.3% | | Base Business Diluted EPS (USD) | $0.91 | $0.87 | +5% | - GAAP Gross profit margin and Base Business Gross profit margin both increased by **70 basis points** to **60.3%**[6](index=6&type=chunk) - Colgate maintained global market leadership in toothpaste with a **41.4%** year-to-date share and manual toothbrushes with a **32.2%** year-to-date share[6](index=6&type=chunk)[7](index=7&type=chunk) [Management Commentary and Outlook](index=2&type=section&id=Management%20Commentary%20and%20Outlook) [Executive Summary](index=2&type=section&id=Executive%20Summary) The CEO highlighted consistent organic sales growth, increased advertising investment due to strong margins, and ongoing strategic investments in digital and data analytics - This marks the **sixth consecutive year** with organic sales growth at or above the **3% to 5%** targeted range[9](index=9&type=chunk) - Strong margin performance enabled a **15% increase** in advertising spending in 2024, following a **19% increase** in 2023[10](index=10&type=chunk) - The company is building income statement flexibility to continue investing in scaling digital and data analytics capabilities[10](index=10&type=chunk) - The CEO expressed confidence in delivering consistent, compounded earnings per share growth in 2025 and beyond[11](index=11&type=chunk) [Full Year 2025 Guidance](index=3&type=section&id=Full%20Year%202025%20Guidance) Colgate anticipates roughly flat net sales in 2025 due to foreign exchange, with **3% to 5% organic sales growth**, gross margin expansion, and low to mid-single-digit EPS growth - Net sales are expected to be roughly flat, including a **mid-single-digit negative impact** from foreign exchange[12](index=12&type=chunk) - Organic sales growth is expected to be within the long-term targeted range of **3% to 5%**[12](index=12&type=chunk) - On a non-GAAP (Base Business) basis, the company expects gross profit margin expansion and **low to mid-single-digit earnings-per-share growth**[12](index=12&type=chunk) [Divisional Performance (Q4 2024)](index=4&type=section&id=Divisional%20Performance) [Sales by Division](index=4&type=section&id=Fourth%20Quarter%20Sales%20Growth%20By%20Division) Q4 2024 organic sales grew **4.3%** across divisions, led by Africa/Eurasia and Latin America, despite significant foreign exchange headwinds impacting net sales Fourth Quarter Sales Growth By Division (%) | % change 4Q 2024 vs. 4Q 2023 | Net Sales (%) | Organic Sales* (%) | Volume (%) | Pricing (%) | FX (%) | | :--- | :--- | :--- | :--- | :--- | :--- | | North America | -1.0% | -0.7% | +1.9% | -2.7% | -0.3% | | Latin America | -7.2% | +9.2% | +0.9% | +8.3% | -16.4% | | Europe | +4.9% | +4.5% | +1.7% | +2.7% | +0.4% | | Asia Pacific | +3.7% | +3.8% | +5.8% | -2.0% | —% | | Africa/Eurasia | +2.8% | +9.4% | +11.5% | -2.1% | -6.6% | | Hill's | +2.3% | +2.9% | +0.8% | +2.0% | -0.5% | | **Total Company** | **-0.1%** | **+4.3%** | **+2.5%** | **+1.8%** | **-4.4%** | [Operating Profit by Division](index=4&type=section&id=Fourth%20Quarter%20Operating%20Profit%20By%20Division) Q4 2024 total operating profit decreased **1%**, with Hill's Pet Nutrition driving **19%** profit growth and **340 basis point** margin expansion, while North America declined Fourth Quarter Operating Profit By Division (Millions USD) | (Millions USD) | 4Q 2024 | % Change vs 4Q 2023 (%) | % to Net Sales (%) | Change in basis points vs 4Q 2023 (basis points) | | :--- | :--- | :--- | :--- | :--- | | North America | $206 | -11% | 19.9% | -220 | | Latin America | $339 | -8% | 30.6% | -10 | | Europe | $155 | 3% | 23.3% | -40 | | Asia Pacific | $211 | 4% | 29.1% | +10 | | Africa/Eurasia | $58 | -1% | 21.5% | -80 | | Hill's | $275 | 19% | 24.1% | +340 | | **Total Company, As Reported** | **$1,064** | **-1%** | **21.5%** | **-20** | [Detailed Financial Statements](index=8&type=section&id=Detailed%20Financial%20Statements) [Consolidated Statements of Income](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income) Full year 2024 saw net sales grow to **$20.1 billion** and net income to **$2.9 billion**, while Q4 net sales were flat at **$4.9 billion** with increased advertising spend Consolidated Statements of Income - Full Year (Millions USD) | For the Twelve Months Ended Dec 31, (Millions USD) | 2024 | 2023 | | :--- | :--- | :--- | | Net Sales (Millions USD) | $20,101 | $19,457 | | Gross Profit (Millions USD) | $12,161 | $11,326 | | Operating Profit (Millions USD) | $4,268 | $3,984 | | Net Income Attributable to Colgate-Palmolive (Millions USD) | $2,889 | $2,300 | | Diluted EPS (USD) | $3.51 | $2.77 | Consolidated Statements of Income - Fourth Quarter (Millions USD) | For the Three Months Ended Dec 31, (Millions USD) | 2024 | 2023 | | :--- | :--- | :--- | | Net Sales (Millions USD) | $4,944 | $4,950 | | Gross Profit (Millions USD) | $2,982 | $2,950 | | Operating Profit (Millions USD) | $1,064 | $1,072 | | Net Income Attributable to Colgate-Palmolive (Millions USD) | $739 | $718 | | Diluted EPS (USD) | $0.90 | $0.87 | [Consolidated Balance Sheets](index=10&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of December 31, 2024, total assets decreased to **$16.05 billion**, total debt was reduced to **$7.95 billion**, and shareholders' equity declined to **$212 million** Consolidated Balance Sheets (Millions USD) | As of December 31, (Millions USD) | 2024 | 2023 | | :--- | :--- | :--- | | Total assets | $16,046 | $16,393 | | Total debt | $7,949 | $8,549 | | Total liabilities | $15,502 | $15,436 | | Total Colgate-Palmolive Company shareholders' equity | $212 | $609 | [Consolidated Statements of Cash Flows](index=11&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash from operations increased to **$4.11 billion** in 2024, driving free cash flow to **$3.55 billion**, with significant cash returned to shareholders Consolidated Statements of Cash Flows (Millions USD) | For the Twelve Months Ended Dec 31, (Millions USD) | 2024 | 2023 | | :--- | :--- | :--- | | Net cash provided by operations | $4,107 | $3,745 | | Capital expenditures | ($561) | ($705) | | **Free cash flow before dividends** | **$3,546** | **$3,040** | | Dividends paid | ($1,789) | ($1,749) | | Purchases of treasury shares | ($1,739) | ($1,128) | | Net increase (decrease) in Cash and cash equivalents | $130 | $191 | [Segment and Geographic Analysis](index=12&type=section&id=Segment%20and%20Geographic%20Analysis) [Segment Information (Net Sales & Operating Profit)](index=12&type=section&id=Segment%20Information) Oral, Personal and Home Care remained the largest segment, while Hill's Pet Nutrition significantly grew sales to **$4.5 billion** and operating profit to **$965 million** in 2024 Full Year Net Sales by Segment (Millions USD) | Full Year Net Sales (Millions USD) | 2024 | 2023 | | :--- | :--- | :--- | | Total Oral, Personal and Home Care | $15,618 | $15,167 | | Pet Nutrition | $4,483 | $4,290 | | **Total Net Sales** | **$20,101** | **$19,457** | Full Year Operating Profit by Segment (Millions USD) | Full Year Operating Profit (Millions USD) | 2024 | 2023 | | :--- | :--- | :--- | | Total Oral, Personal and Home Care | $4,088 | $3,882 | | Pet Nutrition | $965 | $806 | | Corporate | ($784) | ($704) | | **Total Operating Profit** | **$4,268** | **$3,984** | [Geographic Sales Analysis](index=13&type=section&id=Geographic%20Sales%20Analysis%20Percentage%20Changes) Full year 2024 organic sales grew **7.4%**, led by Emerging Markets, despite significant foreign exchange headwinds moderating reported net sales growth to **3.3%** Full Year Geographic Sales Analysis (%) | Full Year 2024 vs 2023 | Sales Change As Reported (%) | Organic Sales Change (%) | Volume (%) | Pricing (%) | Foreign Exchange (%) | | :--- | :--- | :--- | :--- | :--- | :--- | | **Total Company** | **3.3%** | **7.4%** | **3.1%** | **4.4%** | **(4.1)%** | | Emerging Markets | 3.0% | 12.2% | 4.0% | 8.2% | (9.2)% | | Developed Markets | 3.5% | 3.6% | 2.3% | 1.3% | —% | Fourth Quarter Geographic Sales Analysis (%) | Q4 2024 vs 2023 | Sales Change As Reported (%) | Organic Sales Change (%) | Volume (%) | Pricing (%) | Foreign Exchange (%) | | :--- | :--- | :--- | :--- | :--- | :--- | | **Total Company** | **(0.1)%** | **4.3%** | **2.5%** | **1.8%** | **(4.4)%** | | Emerging Markets | (2.2)% | 7.5% | 3.7% | 3.8% | (9.7)% | | Developed Markets | 1.6% | 1.7% | 1.5% | 0.3% | (0.2)% | [Non-GAAP Reconciliations](index=15&type=section&id=Non-GAAP%20Reconciliations) [Q4 2024 Non-GAAP Reconciliation](index=15&type=section&id=Non-GAAP%20Reconciliations%20For%20the%20Three%20Months%20Ended%20December%2031) Q4 2024 GAAP operating profit of **$1,064 million** and diluted EPS of **$0.90** were adjusted to higher non-GAAP figures after accounting for specific charges Fourth Quarter 2024 Non-GAAP Reconciliation (Millions USD) | Q4 2024 (Millions USD) | As Reported (GAAP) | Adjustments | Non-GAAP | | :--- | :--- | :--- | :--- | | Operating Profit (Millions USD) | $1,064 | $7 | $1,071 | | Net Income Attributable to Colgate (Millions USD) | $739 | $6 | $745 | | Diluted Earnings Per Share (USD) | $0.90 | $0.01 | $0.91 | [Full Year 2024 Non-GAAP Reconciliation](index=17&type=section&id=Non-GAAP%20Reconciliations%20For%20the%20Twelve%20Months%20Ended%20December%2031) Full year 2024 GAAP operating profit of **$4,268 million** and diluted EPS of **$3.51** were adjusted to higher non-GAAP figures after accounting for specific charges Full Year 2024 Non-GAAP Reconciliation (Millions USD) | Full Year 2024 (Millions USD) | As Reported (GAAP) | Adjustments | Non-GAAP | | :--- | :--- | :--- | :--- | | Operating Profit (Millions USD) | $4,268 | $85 | $4,353 | | Net Income Attributable to Colgate (Millions USD) | $2,889 | $73 | $2,962 | | Diluted Earnings Per Share (USD) | $3.51 | $0.09 | $3.60 | [Supplementary Information](index=5&type=section&id=Supplementary%20Information) [About Colgate-Palmolive & Investor Information](index=5&type=section&id=About%20Colgate-Palmolive) Colgate-Palmolive is a global consumer products company focused on Oral Care, Personal Care, Home Care, and Pet Nutrition, with upcoming investor events - The company focuses on four core business areas: Oral Care, Personal Care, Home Care, and Pet Nutrition[20](index=20&type=chunk) - The company will host a conference call and webcast on January 31, 2025, to discuss results, with materials available on its investor website[18](index=18&type=chunk)[19](index=19&type=chunk) - The annual meeting of stockholders is scheduled for Friday, May 9, 2025[20](index=20&type=chunk) [Important Disclosures and Definitions](index=5&type=section&id=Cautionary%20Statement%20and%20Non-GAAP%20Measures) This section provides cautionary statements on forward-looking information and defines key non-GAAP financial measures for clearer business trend analysis - The report contains forward-looking statements based on management's current plans and assumptions, which are not guarantees of future performance; investors should refer to SEC filings for risk factors[23](index=23&type=chunk)[24](index=24&type=chunk) - Organic sales growth is a non-GAAP measure excluding foreign exchange, acquisitions, and divestments to show underlying sales trends[25](index=25&type=chunk)[27](index=27&type=chunk) - Base Business results are non-GAAP measures excluding non-recurring items like restructuring, litigation, and product recall costs[26](index=26&type=chunk)[27](index=27&type=chunk) - Market share data relies on third-party vendors and internal estimates, subject to limitations such as the exclusion of certain retail channels like eCommerce[21](index=21&type=chunk)[22](index=22&type=chunk)

Colgate-Palmolive Company CL will release earnings results for its fourth quarter before the opening bell on Friday, Jan. 31, 2025.Analysts expect the New York-based company to report quarterly earnings at 89 cents per share, up from 87 cents per share in the year-ago period. Colgate-Palmolive projects to report revenue of $4.99 billion for the recent quarter, compared to $4.95 billion a year earlier, according to data from Benzinga Pro.On Dec. 11, the company's Board of Directors declared a quarterly cash ...

Core Viewpoint - Colgate-Palmolive Company (CL) is anticipated to report growth in both revenue and earnings for the fourth quarter of 2024, with revenue expected to reach $5 billion, reflecting a 1.2% increase year-over-year, and earnings estimated at 89 cents per share, indicating a 2.3% growth from the previous year [1][2]. Revenue and Earnings Estimates - The Zacks Consensus Estimate for fourth-quarter revenues is $5 billion, up 1.2% from the same quarter last year [1]. - The consensus estimate for earnings is 89 cents per share, suggesting a growth of 2.3% year-over-year [2]. Earnings Performance - In the last reported quarter, Colgate's earnings exceeded the consensus estimate by 3.4%, with an average earnings surprise of 3.8% over the trailing four quarters [2]. Earnings Prediction Model - The current Earnings ESP for Colgate is -0.91%, and it holds a Zacks Rank of 3 (Hold), indicating that the model does not predict a definitive earnings beat this season [3]. Business Momentum and Growth Drivers - Colgate's fourth-quarter performance is expected to benefit from strong business momentum, pricing strategies, and productivity initiatives, with a focus on balanced organic sales growth across all categories [4]. - The company is projected to achieve organic sales growth of 6.5%, with significant improvements in various regions, including 12% in Latin America and 9% in Europe [5]. Gross Margin and Profitability - The adjusted gross margin is expected to expand by 210 basis points to 61.7%, with a 5.6% year-over-year increase in adjusted gross profit [7]. - Colgate has been experiencing a sequential rise in gross margin due to strong pricing and revenue growth management initiatives [6]. Challenges and Headwinds - The company faces challenges such as volume softness in China and lower private label growth, which may slightly impact top-line performance [8]. - Higher raw material costs and inflationary foreign exchange pressures are also expected to offset some gross margin growth [9]. SG&A Expenses - SG&A expenses are anticipated to rise by 6.9% year-over-year, reaching 38.2% of sales, reflecting continued investment in digital and analytics capabilities [10]. Stock Performance and Valuation - Colgate's shares have increased by 8.7% over the past year, outperforming the broader industry growth of 0.9% but underperforming the S&P 500 index, which grew by 24.8% [11]. - The stock trades at a forward P/E multiple of 24.04X, higher than the industry average of 21.43X and the S&P 500's average of 22.64X, indicating a relatively pricey valuation [14].